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Aims Adiponectin (APN) is an immunomodulatory and cardioprotective adipocytokine. Toll-like receptor (TLR) 4 mediates
autoimmune reactions that cause myocarditis resulting in inflammation-induced cardiac injury. Here, we investigated
whether APN inhibits inflammation and injury in autoimmune myocarditis by interfering with TLR4 signalling.
Methods
and results
APN overexpression in murine experimental autoimmune myocarditis (EAM) down-regulated cardiac expression of TLR4
and its downstream targets tumour necrosis factor (TNF)a, interleukin (IL)-6, IL-12, CC chemokine ligand (CCL)2, and
intercellular adhesion molecule (ICAM)-1 resulting in reduced infiltration with cluster of differentiation (CD)3+,
CD14+, andCD45+ immunecells aswell asdiminished myocardial apoptosis. ExpressionofTLR4 signallingpathwaycom-
ponents was unchanged in hearts and spleens of APN-knockout (APN-KO) mice. In vitro APN had no effect on TLR4 ex-
pression in cardiac and immune cells but induced dissociation of APN receptors from the activated TLR4/CD14 signalling
complex. APN inhibited the expression of a TLR4-mediated inflammatory phenotype induced by exogenous and endogen-
ous TLR4 ligands as assessed by attenuated nuclear factor (NF)-kB activation and reduced expression of TNFa, IL-6, CCL2,
and ICAM-1. Accordingly, following TLR4 ligation, splenocytes fromAPN-KO mice showed enhanced expressionofTNFa,
IL-6, IL-12, CCL2, and ICAM-1, whereas dendritic cells (DCs) from APN-KO mice demonstrated increased activation and
T-cell priming capacity. Moreover, APN diminished TLR4-mediated splenocyte migration towards cardiac cells as well as
cardiomyocyte apoptosis after co-cultivation with splenocytes. Mechanistically, APN inhibited TLR4 signalling through
cyclooxygenase (COX)-2, protein kinase A (PKA), and meiosis-specific serine/threonine kinase (MEK)1.
Conclusion Our observations indicate that APN protects against inflammation and injury in autoimmune myocarditis by diminishing
TLR4 signalling thereby attenuating inflammatory activation and interaction of cardiac and immune cells.
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1. Introduction
Inflammation can generate severe and irreversible damage to the myo-
cardium, because persistent inflammation underlies the pathogenesis
and progression of many common cardiovascular diseases such as myo-
cardial infarction (MI), atherosclerosis, hypertrophy,myocarditis, dilated
cardiomyopathy, and heart failure.1
Toll-like receptors (TLRs) are key recognition components of the
innate immune system and also crucial for the activation of adaptive
immunity. In addition to their pivotal role in host immune defences
against invading pathogens, TLRs are also capable of modulating inflam-
mation following non-infectious stress insults such as ischaemia in
various tissues including the heart.2
TLR4 specifically recognizes Gram-negative bacterial lipopolysac-
charide (LPS). Moreover, it binds to a heterogeneous group of endogen-
ous ligands such as heat shock proteins (e.g. HSP60) and extracellular
matrix breakdown products that are typically released into the myocar-
dium in the context of cardiac injury.2 Binding of such endogenous
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ligands by TLR4 following cardiac injury triggers immune responses and
contributes to the origination or augmentation of inflammation.3 Thus,
the TLR4 signalling pathway is an important mediator of autoimmune
reactions that cause inflammation-induced injury in the myocardium.
In this regard, TLR4 signalling has been shown to mediate myocardial is-
chaemia/reperfusion (I/R) injury,4 maladaptive remodelling,3 increased
infarct size and reduced survival after MI.5 Moreover, TLR4 has been
demonstrated to be essential for the induction of experimental auto-
immune myocarditis (EAM) by cardiac myosin.6 Taken together, the
TLR4 signalling pathway is considered to be a major contributor for
the progression of important inflammation related cardiovascular dis-
eases representing a promising target for therapeutic interventions.
Adiponectin (APN) is an abundant plasma cytokine, that is primarily
expressed in adipocytes.7 Moreover, APN expression has also been
shown for endothelial cells, skeletal myocytes, and cardiac cells.7 APN
exists as full-length protein in several oligomeric forms or as proteolytic
cleavage fragment in high concentrations of 3–30 mg/mL in human
plasma.7 APN functions as important modulator of immune reactions
exerting a wide spectrum of anti-inflammatory effects.7 Results of in
vitro experiments demonstrate that APN inhibits the activation of the
pro-inflammatory transcription factor nuclear factor (NF)-kB and ex-
pression of tumour necrosis factor (TNF)a in endothelial cells.8 More-
over, APN suppresses immune cell activation,9 adhesion to target cells,8
and controls antigen-specific expansion of T cells.10 Accordingly, results
from in vivo studies show that APN mediates cardioprotection by modu-
lation of inflammatory responses. APN conferred resistance against
cardiac injury following ischaemia11 and attenuated myocardial
damage in viral myocarditis.12 Moreover, recently it has been shown
that APN favours positive outcome in patients with inflammatory car-
diomyopathy by inhibiting cardiac inflammation and remodelling.13
Here, we investigated whether APN is protective against TLR4-
mediated myocardial inflammation and injury. Therefore we examined
the effects of systemic APN overexpression on inflammation and apop-
tosis in the TLR4-dependent animal model of EAM. The underlying
mechanisms of APN effects were studied in cardiac and immune cell
culture.
2. Methods
2.1 Animals and mouse model of EAM
The mouse model of EAM has been described previously.14 Replication de-
fective adenoviral vectors (3× 108 plaque forming units) expressing mouse
APN (Ad-APN) or control vectors (Ad-RR5) were injected intravenously
into8–10-week-old femaleBALB/cmice (purchased fromJacksonLaborator-
ies) 1 week before induction of EAM (Day –7) leading to robust transduction
andAPNexpression in the liver that canbedetected in theplasmaas longas28
days. For EAM induction, mice were immunized with 200 mL of a 1:1 emulsion
of PBS with 1 mg/mL of a heart muscle specifica-myosin heavy chain-derived
peptide (MyHC-a614–629 [Ac-SLKLMATLFSTYASAD-OH]) in complete
Freund’s adjuvant (CFA) at Days 0 and 7. Control mice received PBS/CFA
only.TheEAManimalswererandomlyallocated to twogroupsandwere intra-
venously injected with either Ad-APN or control vector (Ad-RR5). Investiga-
torswereunawareof the treatmentgroupsofanimals.Allmicewere sacrificed
for further examinations at the inflammatory peak of EAM on Day 21 post-
immunization.
For cell isolation, APN-knockout (APN-KO) mice and the corresponding
C57BL/6 wild-type (WT) mice were purchased from Jackson Laboratories.
Neonatal Wistar Harlan rats were purchased from FEM Berlin (Germany).
The investigation conformed to the US NIH Guide for the Care and Use of
Laboratory Animals (8th Edition, published 2011) and was approved by the
respective authorities in Basel (Switzerland) and Berlin (Germany)—No:
T 0086/10. Before injections and euthanization, animals were anaesthetized
by inhalation of 2.0 vol% isoflurane for 5 min using an automatic delivery
system. Adequate anaesthesia was tested by monitoring withdrawal
response to foot pinch. Mice were euthanized by cervical dislocation and
neonatal rats by decapitation.
2.2 RT2Profiler PCR-array and quantitative
real-time polymerase chain reaction
RNA from tissues and cultured cells was extracted by using TRIzol (Invitro-
gen) and the RNeasy Mini Kit (Qiagen). RNA integrity was checked by 2100
Bioanalyzer (Agilent Technologies). The RT2 Profiler mouse chemokines
and chemokine receptors PCR-Array System (SABiosciences) was used as
suggested by the manufacturer. Quantitative real-time polymerase chain re-
action (qRT-PCR) was performed by using High capacity cDNA Reverse
Transcription Kit, TaqMan Universal PCR Master Mix, and TaqMan gene ex-
pression assays from Applied Biosystems.
2.3 Cell culture and reagents
Neonatal cardiomyocytes and fibroblasts were prepared from hearts of
1–3-day-old Wistar Harlan rats as described.15 Neonatal rat and mouse
splenocytes were isolated from spleens of 1–3-day-old Wistar Harlan rats
or 6–8-week-old male APN-KO and WT mice, respectively. Mouse DCs
were enriched by cultivation of isolated bone marrow cells from
6–8-week-old male APN-KO and WT mice as described.16 Peripheral
blood mononuclear cells were isolated from heparinized blood of healthy
human donors using ficoll density gradient centrifugation. Recombinant
human full-length APN produced in a mammalian expression system was
purchased from R&D Systems; determined endotoxin contamination
(Kinetic-QCL, Lonza) was ,10 pg/mg protein. TLR4-grade LPS was pur-
chased from Enzo Life Sciences, rat fibrinogen from Sigma-Aldrich; endo-
toxin contamination was ,50 pg/mg. BAY 11-7085, NS-398, Rp-cAMP,
PD 098 059, and Wortmannin were purchased from Sigma-Aldrich. For all
cell-culture experiments, investigators were blinded to the performed treat-
ment of cells.
2.4 Fluorescence-activated cell sorting
Phenotypic analysis of immune cells was performed with fluorescence-
conjugated antibodies against murine CD3, CD11c, and CD86 (BioLegend)
and human CD3, CD14, CD19, BDCA-1, TLR4, and TNFa (BD Pharmin-
gen). For the measurement of DC induced T cell proliferation 2 × 104
DCs from APN-KO or WT mice and 2 × 105 CFDA (Vybrantw CFDA SE
Cell Tracer Kit, Molecular Probes, Invitrogen) labelled allogenic splenocytes
from 6–8 weeks old BALB/c mice were co-cultivated for 4 days.
2.5 Protein analysis
NF-kBactivation inwholecell lysateswasmeasuredusing theTransAMNF-kB
p65 subunit DNA-binding ELISA (Active Motif)13 that specifically detects
nuclear (i.e. activated) NF-kB. IkBa phosphorylation was determined by
immunoblot using anti-Phospho-IkBa (Cell Signaling Technologies) and
anti-a-Tubulin (Calbiochem) antibodies. TNFa and CCL2 levels (R&D
Systems) in cell-culture media as well as Troponin I levels (Life Diagnostics)
in sera were quantified using ELISA kits as suggested by the manufacturers.
Cardiac protein expression of CCL2 was measured using the RayBiow
Mouse Cytokine Antibody Array 3 (Ray Biotech). Cardiac protein expression
ofTLR4, ICAM-1, and GAPDH wasquantified by immunoblotusing anti-TLR4
(Imgenex), anti-ICAM-1 (Santa Cruz), and anti-GAPDH (Cell Signaling
Technologies) antibodies. Receptor interactions between TLR4, CD14, and
APN receptors were analysed via immunoprecipitation using anti-TLR4
(Imgenex), anti-CD14 (Santa Cruz), and anti-APN-R1 (Phoenix Peptides)
antibodies.
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2.6 Migration assay
3.0 × 104 cardiomyocytes or fibroblasts were seeded into the lower re-
ceiver plate of HTS Transwellw 96-well permeable support systems
(8 mm membrane pore size, Corning Life Science), cultured in DMEM con-
taining 0.2% FBS and stimulated with LPS in the presence or absence of APN.
For the measurement of immune cell migration towards the cardiac cells,
1.5 × 105 CFDA (Vybrantw CFDA SE Cell Tracer Kit, Molecular Probes,
Invitrogen) labelled rat splenocytes were added to the upper insert plate
wells. After co-cultivation of cardiac cells and splenocytes for 24 h, cells in
the lower receiver plate wells were harvested and resuspended in 100 mL
PBS + 2% Flebogamma. Fifteen microlitres of a 1:10 dilution of polystyrene
beads (CompBead, BD Biosciences) was added to the samples for normal-
ization. Quantification of migrated splenocytes was performed by
fluorescence-activated cell sorting (FACS) analysis gating on the bead popu-
lation and measuring an uptake of exactly 1 × 104 beads per approach.
Counted was the number of CFDA+ cells that were collected in parallel
after exclusion of the bead population.
2.7 Analysis of apoptosis
Cardiomyocyte apotosis after co-cultivation with splenocytes (cell number
ratio 1:4) wasquantified by TUNEL using the In Situ Cell Death Detection Kit
TMR red (Roche Applied Science). Co-cultivated splenocytes were
removed by washing with PBS. Apoptosis in myocardial cryosections
(5 mm) was determined by TUNEL staining using the In Situ Cell Death De-
tection Kit Fluorescein (Roche Applied Science).
2.8 Statistical analysis
SPSS 20 or SAS 9.3 were used for statistical data analysis. Differential impact
of APN depending on stimulation has been modelled via factorial ANOVA
with the interaction between treatment and stimulation. The non-
parametric ANOVA type analyses by Brunner have been performed in
case of normality assumption being violated or Levene’s test of homogeneity
being significant. Pair-wise comparisons between individual groups were
done using the Mann–Whitney U test. Differences were considered statis-
tically significant at a two-sided value of P, 0.05. No Bonferroni adjustment
has been performed.
For sample size calculation, a type I error of 0.05 and type II error of 0.1
were considered acceptable for an animal study. Reduction of the number
of CD45 cells in the heart was chosen as the primary endpoint in our
study and based on a previous pilot study, we assumed a large effect size
through APN. Sample size calculation was performed with the G*Power 3
(University of Du¨sseldorf, Germany) and resulted in n ¼ 6 per group.
.
3. Results
3.1 APN overexpression in EAM reduces
cardiac expression of TLR4 and its major
downstream targets
To investigate the effect of systemic APN overexpression in
TLR4-dependent EAM, mRNA and protein expression analysis in the
hearts of mice was performed (Figure 1A and B, Supplementary material
online, Figure S1). Induction of EAM led to an increase of cardiac expres-
sion of TLR4 and several important chemokines (i.e. CC chemokine
ligand (CCL)2), pro-inflammatory cytokines (i.e. interleukin (IL)-6,
IL-12, and TNFa), and adhesion molecules (i.e. intercellular adhesion
molecule (ICAM)-1) that are collectively involved in the induction and
progression of EAM. Following APN gene transfer, however, cardiac ex-
pression of TLR4 was significantly reduced (P ¼ 0.016, EAM RR5 vs.
EAMAPN, respectively). This reduction wasassociatedwith significantly
decreased expression of pro-inflammatory cytokines TNFa, IL-6, and
IL-12, as well as the chemokine CCL2 and ICAM-1, all representing
downstream targets of TLR4 (Figure 1A and B, Supplementary material
online, Figure S1). In order to investigate whether APN directly regulates
the expression of central components of the TLR4 signalling pathway
WT and APN-KO mice were examined. Neither TLR4, myeloid differ-
entiation primary response gene 88 (MyD88), TIR-domain-containing
adapter-inducing interferon-ß (TRIF) nor interferon regulatory factor
(IRF)3 were differentially expressed in the hearts and spleens of
APN-KO mice (Supplementary material online, Figure S2A and B).
Thus, our results indicate that APN attenuates inflammation in EAM
by inhibiting TLR4 signalling.
3.2 APN overexpression in EAM
attenuates immune cell infiltration
and myocardial injury
Chemokines, inflammatory cytokines, and adhesion molecules partici-
pate in homing, accumulation, and activation of immune cells in inflamed
tissues.1 Following EAM induction, up-regulation of CCL2 and ICAM-1
expression was observed associated with accumulation of leucocytes
within the heart (Figure 1B and C ). Accordingly, down-regulation of
CCL2 and ICAM-1 following APN gene transfer was accompanied by
reduced cardiac mononuclear cell infiltration. Specifically, cluster of dif-
ferentiation (CD)3+ T cell (P ¼ 0.030) and CD45+ leucocyte accumu-
lation (P ¼ 0.030) were diminished in APN overexpressing animals
(Figure 1C). Furthermore, expression of CD14, a marker for monocytes
playing an important role in the progression of EAM,17 was significantly
down-regulated following APN gene transfer (Figure 1C). Persistent ac-
cumulation and activation of mononuclear cells within the heart is asso-
ciated with increased tissue injury mediated by cytokines, reactive
oxygen species (ROS), and proteolytic enzymes.1 Therefore, apoptotic
cell death in cardiac tissue sections of EAM mice as well as cardiac spe-
cific serum Troponin I were assessed. The amount of apoptosis assessed
by TUNEL (P ¼ 0.029) staining and Troponin I (P ¼ 0.008) concentra-
tions were significantly increased in mice following EAM induction
(Figure 2A and B). APN gene transfer, however, significantly attenuated
apoptosis (P ¼ 0.029) and Troponin I (P ¼ 0.030) increase in this
model. Taken together, our data indicate that APN inhibits immune
cell infiltration, inflammation, and tissue injury in autoimmune
myocarditis.
3.3 APN inhibits TLR4-mediated
expression of an inflammatory phenotype
on cardiac cells
Incubation of cardiomyocytes and fibroblasts as well as immune cells (i.e.
CD14+, CD19+, and DCs) with APN had no effect on TLR4 mRNA
(data not shown) or protein expression in vitro (Supplementary material
online, Figure S2C) supporting our data in APN-KO mice. Therefore, we
investigated whether APN inhibited intracellular TLR4 signal transduc-
tion. The chemokine CCL2 and the adhesion molecule ICAM-1 are es-
sential factors for the targeted activation of immune cells during
inflammation. Whereas CCL2 plays a major role as a chemoattractant
for the infiltration of immune cells into the myocardium, ICAM-1
enables their firm adhesion to cardiac cells.1 As shown in Figure 3A, incu-
bation of cardiomyocytes with LPS, a potent exogenous TLR4 signalling
activator, triggered a significant up-regulation of CCL2 and ICAM-1
expression. Similar results were obtained when cells were stimulated
by fibrinogen, an endogenous TLR4 ligand that is released in the
context of tissue injury (Supplementary material online, Figure S3A).
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However, APN incubation significantly attenuated TLR4-mediated up-
regulation of CCL2 and ICAM-1 mRNA expression caused by both
LPS and fibrinogen. Moreover, up-regulation of the pro-inflammatory
cytokines TNFa and IL-6 after TLR4 ligation by LPS and fibrinogen in car-
diomyocytes and fibroblasts was significantly diminished following APN
incubation (Figure 3A and D; Supplementary material online, Figures S3
and S4). Taken together, APN inhibited the expression of a
TLR4-mediated pro-inflammatory phenotype on cardiac cells, while
APN had no effect in unstimulated cells. These results indicate that
APN exerts its anti-inflammatory effects by inhibiting TLR4 signal trans-
duction rather than inhibiting expression of TLR4 or downstream com-
ponents of its signalling pathway.
3.4 APN inhibits TLR4-mediated NF-kB
activation in cardiomyocytes
NF-kB represents the central downstream transcription factor in the
TLR4 signalling pathway controlling the expression of major
pro-inflammatory targets such as TNFa, IL-6, ICAM-1, and CCL2 (Sup-
plementary material online, Figure S5). Following TLR4 ligation by LPS,
NF-kB is rapidly activated in cardiomyocytes (Figure 3B). APN treatment
led to a significant inhibition of TLR4-mediated NF-kB activation
(P ¼ 0.032) while no APN effect was observed in unstimulated cells.
In order to further elucidate the mechanisms involved in the inhibition
of NF-kB activation by APN, TLR4-mediated phosphorylation of inhibi-
tor of NF-kB (IkB)awas studied. IkBa phosphorylation primes the mol-
ecule for proteosomal degradation leading to nuclear translocation and
increased transcriptional activity of NF-kB.18 TLR4 ligation by LPS
caused a significant increase in IkBaphosphorylation. However, APN in-
cubation significantly attenuated TLR4-mediated IkBa phosphorylation
(Figure 3C). The observed inhibitory effect of APN on TLR4-induced
NF-kB activation supports the contention that APN effectively attenu-
ates the TLR4 signal transduction process.
3.5 APN inhibits TLR4 signalling in
cardiomyocytes through COX-2-,
PKA-, and MEK1-dependent mechanisms
APN-induced effects are among others mediated through phosphoino-
sitide 3-kinase (PI3K),19 cyclooxygenase (COX)-2, protein kinase A
(PKA), and meiosis-specific serine/threonine kinase (MEK)1.7,8,11 In
order to examine their potential role for the inhibitory effects of
Figure 1 APN overexpression attenuates cardiac inflammation in EAM. Cardiac expression of TLR4 and TLR4 target genes was analysed in mice trans-
duced with a mouse APN expression vector (EAM APN) or control vector (EAM RR5) 21 days after EAM induction. (A) mRNA expression of TNFa, IL-6,
and IL-12 are shown. (B) Representative blots indicating protein expression of TLR4, CCL2 (antibody array), and ICAM-1 are depicted. Box plots indicating
quantitative levels. (C) mRNA expression of CD3, CD14, and CD45 are shown (n ¼ 5–6 animals per group).
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APN, cells were treated with wortmannin (PI3K inhibitor), NS-398
(COX-2 inhibitor), Rp-cAMP (PKA inhibitor), and PD 098 059 (MEK1
inhibitor). Incubation of cardiomyocytes with LPS triggered a significant
up-regulation of IL-6 gene expression that was almost completely abol-
ished by APN (Figure 3D). Whereas NS-398 (P ¼ 0.001), Rp-cAMP (P ¼
0.001), and PD 098 059 (P ¼ 0.001) all partially blocked the APN effect,
wortmannin did not exert any influence (Figure 3D). Importantly, simul-
taneous addition of NS-398, Rp-cAMP, and PD 098 059 to the cell
culture completely abolished the inhibitory effect of APN. Therefore, in-
hibition of TLR4 signal transduction by APN is mediated through
COX-2-, PKA-, and MEK1-dependent mechanisms. In further experi-
ments, a possible direct interaction of APN receptors with TLR4 was
investigated. For APN receptor 1 (APN-R1), an interaction with TLR4
and its co-receptor CD14 could be determined under basic culture con-
ditions (Figure 3E). This interaction was enhanced by LPS incubation.
APNbinding to its receptorcaused adissociation of the ligand–receptor
complex from TLR4/CD14 (Figure 3E) resulting in the inhibition of
downstream signal transduction. Those data implicate APN-R1 in the
stabilization of the TLR4/CD14 signalling complex.
3.6 APN inhibits TLR4-mediated activation
of immune cells
TLR4 signalling is capable of activating not only cardiac, but also immune
cells. Incubation of CD14+ and CD19+ cells as well as DCs with LPS
significantly increased TNFa protein expression (Figure 4A). APN,
however, significantly inhibited TNFa expression after TLR4 ligation
in all three types of immune cells. In order to corroborate these findings,
splenocytes from WT and APN-KO mice were isolated and cultured in
vitro. As illustrated in Figure 4B and Supplementary material online, Figure
S3B, splenocytes derived from APN-KO mice exhibited a significant in-
crease in the mRNA expression of pro-inflammatory cytokines TNFa,
IL-6 and IL-12, the chemokine CCL2 as well as ICAM-1 following
TLR4 ligation compared with their WT littermates, implicating that
APN deficiency promotes activation of immune cells triggered by
TLR4 signalling. TLR4-mediated DC activation represents an essential
trigger for EAM induction.6 Therefore, bone marrow-derived DCs
from APN-KO and WT mice were stimulated with LPS. TLR4 stimula-
tion of DCs from APN-KO mice resulted in significantly increased ex-
pression of the activation marker CD86 when compared with their
WT littermates (P ¼ 0.001, Figure 4C) that was attenuated by APN.
Moreover, DCs from APN-KO mice displayedan enhanced priming cap-
acity following TLR4 ligation (Figure 4D) as they exhibited an increased
ability to induce proliferation of co-cultivated T cells (P ¼ 0.008).
Taken together, those data in immune cells corroborate our findings
in cardiac cells and demonstrate that inhibition of TLR4 signal transduc-
tion by APN is functional in both cell types. Importantly, they underline
the effective role of APN in inhibiting TLR4-dependent priming and ac-
tivation of immune cells that is essential for EAM induction.
3.7 APN attenuates TLR4-mediated
migration of immune cells
In order to further support our hypothesis that APN inhibits TLR4 trig-
gered cardiac inflammation and injury, the interaction between cardiac
and immune cells was examined. First, migration of immune cells
towards TLR4 stimulated cardiac cells was analysed. Up-regulation of
CCL2 and ICAM-1 expression in response to TLR4 ligation should facili-
tate the migration of immune cells into the myocardium leading to
increased accumulation of activated immune cells as observed following
EAM induction. Indeed, TLR4 ligation on cardiomyocytes (P ¼ 0.008)
and fibroblasts (P ¼ 0.004) by LPS significantly increased splenocyte mi-
gration (Figure 5A). However, incubation with APN inhibited the
TLR4-mediated increase of splenocyte migration to cardiomyocytes
(P ¼ 0.032) and fibroblasts (P ¼ 0.004), respectively. Of note, APN
exhibited no detectable effect on migration of splenocytes to
Figure 2 APN overexpression ameliorates cardiac injury in EAM. Troponin I in serum and apoptosis in hearts of mice transduced with a mouse APN
expression vector (EAM APN) or control vector (EAM RR5) was determined 21 days after EAM induction. (A) Left: Upper panel: representative images of
TUNEL stained nuclei (green). Lower panel: related images of DAPI counterstained nuclei (blue). Right: Box plot indicating the number of TUNEL positive
cells relative to the total number of cells (n ¼ 4 animals per group). (B) Troponin I serum levels are indicated (n ¼ 5–6 animals per group).
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unstimulated cardiac cells. Those data indicate that the inhibition of che-
mokine and adhesion molecule expression by APN might explain at least
in part the attenuation of cardiac immune cell accumulation following
APN gene transfer in EAM.
3.8 APN attenuates TLR4-mediated
cardiomyocyte apoptosis
Persistent accumulation of activated immune cells in the areas of inflam-
mation results in injury of surrounding cardiac cells.1 Therefore, in a
second interaction experiment in vitro, the effect of APN on
TLR4-activated cardiomyocytes in co-culture with immune cells was
studied. Apoptosis of cardiomyocytes co-cultivated with freshly isolated
rat splenocytes was significantly increased in the presence of LPS
(Figure 5B and C ). Co-incubation with APN significantly attenuated the
TLR4-mediated increase in cardiomyocyte apoptosis (P ¼ 0.008).
APN alone, however, had no detectable effect on apoptosis of cardio-
myocytes. These data implicate that attenuation of the expression of
an inflammatory phenotype on cardiac cells and inhibition of immune
cell activation may contribute to the attenuation of cardiac injury follow-
ing APN overexpression in EAM.
4. Discussion
In this study, we report for the first time APN interference with TLR4
signalling attenuating myocardial inflammation and injury in EAM. APN
not only ameliorated activation of immune cells by TLR4 but inhibited
Figure 3 APN inhibits expression of a TLR4-mediated inflammatory phenotype on cardiomyocytes. (A) Cardiomyocytes were incubated with APN
(10 mg/mL) or vehicle (Albumin 10 mg/mL) for 18 h before stimulation with or without LPS (1 mg/mL) for 6 h. Expression of TNFa, CCL2 (ELISA), and
ICAM-1 (qRT-PCR) was quantified (n ¼ 6). (B) Cardiomyocytes were incubated with APN (10 mg/mL) or vehicle (Albumin 10 mg/mL) before stimulation
with or without LPS (1 mg/mL) for 90 min. NF-kB activation was determined by ELISA (n ¼ 4–5). (C) Cardiomyocytes were incubated with APN (10 mg/
mL) or vehicle (Albumin 10 mg/mL) before stimulation with or without LPS (1 mg/mL) for 90 min. IkBa phosphorylation was quantified by immunoblot
(n ¼ 4). Box plot indicating IkBa phosphorylation normalized to a-Tubulin in relative units. (D) Cardiomyocytes were pre-treated with wortmannin
(1 mmol/L), NS-398 (10 mmol/L), Rp-cAMP (100 mmol/L), PD 098 059 (20 mmol/L) or vehicle for 1 h, incubated with APN (10 mg/mL) or vehicle
(Albumin 10 mg/mL) for 18 h before stimulation with or without LPS (1 mg/mL) for 6 h. mRNA expression of IL-6 was determined by qRT-PCR.
Results are presented as mean+ SEM in relative units (n ¼ 6–7). (E) APN-R1 co-localizes with TLR4/CD14 signalling complex. Cardiomyocytes were
incubated with LPS (1 mg/mL), APN (10 mg/mL), or vehicle (Albumin 10 mg/mL) for 3 h. Immunoprecipitation (IP) was performed as indicated and
target proteins visualized by immunoblot. Bar graphs indicating mean+ SEM for respective immunoblots (n ¼ 3 independent experiments per group).
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the expression of an inflammatory phenotype in cardiomyocytes and
fibroblasts within the heart mediated by TLR4 ligation and thereby inter-
fered with attraction and activation of immune cells by TLR4-activated
cardiac cells. Mechanistically, APN diminished TLR4-dependent IkBa
phosphorylation and NF-kB activation in a COX-2-, PKA-, and MEK1-
dependent manner and inhibited the interaction of its receptors with
the TLR4/CD14 complex (Figure 6).
In our in vivomodel, cardiac TLR4 expression was down-regulated fol-
lowing APN gene transfer. However, attenuated cardiac infiltration with
CD3+, CD14+, and CD45+ cells that express TLR4 was determined
afterAPNoverexpression. Immunecells expresshighquantitiesofTLRs.
Therefore, decreased expression of TLR4 in EAM following APN gene
transfer might be secondary due to reduced inflammatory cell infiltra-
tion. In line with this hypothesis, APN deficient mice showed no differ-
ence of key TLR4 signalling components and TLR4 on cardiac and
immune cells was not regulated by APN even following LPS stimulation
in vitro. However, down-regulation of TLR4 by yet unknown mechanisms
in EAM in vivo remains a possible explanation, but early regulation of
TLR4 signalling has been shown to be more important than control of
TLR4 expression since low levels of TLR4 can enable signalling.20 Our
in vitro experiments corroborate these findings. APN inhibited
TLR4-mediated phosphorylation of IkBawith subsequent translocation
of NF-kB in a COX-2-, PKA-, and MEK1-dependent manner leading to
diminished expression of TLR4-dependent genes such as TNFa, IL-6,
IL-12, CCL2, and ICAM-1 in cardiac and immune cells in vitro. Moreover,
APN-R1 directly interacts with the TLR4/CD14 signalling complex.
After ligand binding, APN-R1 dissociates from TLR4 and CD14,
thereby inhibiting downstream signalling following LPS stimulation.
This interesting finding clearly needs more investigation in the future.
In line with these observations, interaction of activated cardiac cells,
i.e. cardiomyocytes stimulated by TLR4 ligation with immune cells, i.e.
splenocytes, was significantly inhibited by APN. Here we show that
TLR4 ligation leads to the expression of an inflammatory phenotype
on cardiomyocytes characterized by up-regulation of ICAM-1 and the
pro-inflammatory cytokines TNFa and IL-6. Not only TNFa and IL-6,
but also up-regulated CCL2 from cardiac cells induce homing and acti-
vation of immune cells. CCL2 has been shown to play a major role in
regulating migration of monocytes, T cells, and natural killer (NK) cells
Figure4 APN suppressesTLR4-mediated activationof immunecells. (A)Human CD14+ (monocytes), CD19+ (Bcells), anddendritic cells (DCs)were
incubated with APN (3 mg/mL) or vehicle for 24 h before stimulation with or without LPS (100 ng/mL) for 16 h. TNFaexpression wasdetermined by FACS
(n ¼ 4). (B) Splenocytes from APN-KO and WT mice were stimulated with or without LPS (100 ng/mL) for 3 h. mRNA expression of TNFa, CCL2, and
ICAM-1 was determined by qRT-PCR (n ¼ 4–5). (C) DCs from APN-KO and WT mice were stimulated with or without LPS (100 ng/mL) in the presence
or absence of APN (3 mg/mL) for 24 h. Expression of CD86 on activated DCs (CD11c+ CD86+ cells) was determined by FACS. Box plot illustrates DC
activation status (n ¼ 8). (D) DCs from APN-KO and WT mice were stimulated with or without LPS (100 ng/mL) for 24 h before being added to allogenic
CFDA-labelled splenocytes for 4 days. T-cell proliferation was determined by FACS (n ¼ 5). Box plot illustrates DC-mediated proliferation of activated
T cells (CD3+ CD86+ cells).
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to an inflammatory focus. Recently, it has been shown that CCL2 is up-
regulated in EAM in rodents as well as patients with myocarditis, and
blocking of CCL2 with monoclonal antibodies reduced the severity of
autoimmune myocarditis.21 In contrast, CCL2 overexpression within
the heart leads to the induction of myocarditis.22 Moreover, mice defi-
cient in CCR2, the receptor of CCL2, exhibit a reduced prevalence
and severity of EAM.22 In our model, EAM led to a pronounced up-
regulation of cardiac CCL2 that was significantly attenuated following
APN gene-transfer. Furthermore, APN significantly diminished CCL2
expression following TLR4 ligation in cardiac cells in vitro. Indeed, we
show a diminished migration of splenocytes to TLR4- activated cardio-
myocytes and fibroblasts in vitro. Moreover, less CD3+, CD14+, and
CD45+ immune cells were detected in the myocardium of EAM mice
21 days following APN gene transfer, indicating that APN interferes
with TLR4-mediated up-regulation of CCL2 in vivo.
Besides CCL2, expression of the TLR4 target genes TNFa, IL-6, IL-12
was diminished in EAM following APN gene transfer. TNFa is a major
pro-inflammatory cytokine inducing apoptosis, ROS, and reduction of
left-ventricular ejection fraction.23 Transgenic mice cardio-specifically
overexpressing TNFadevelop cardiomyopathy characterized by exten-
sive cardiac inflammation,23 and increased plasma concentrations of
TNFa are found in patients with congestive heart failure and dilated car-
diomyopathy.13 IL-6 is essential in the pathogenesis of EAM, because its
deletion leads to diminished prevalence and severity of autoimmune
myocarditis due to a lack of expansion of critical CD4+ T cells as well
as diminished production of complement C3, a crucial factor for the de-
velopment of myocarditis.14 Moreover, IL-6 mediates the differentiation
of T helper 17 (Th17) cells, that play an important role in the initiation of
EAM. Similar to IL-6, IL-12 promotes the development of autoimmune
myocarditis by regulating autoreactive CD4+ T cell proliferation as
well as autoreactive CD8+ T cell differentiation.24 Taken together,
down-regulation of TNFa, IL-6, and IL-12 expression levels by APN in
a TLR4-dependent manner might in part explain the observed attenu-
ation of cardiac inflammation in EAM following APN overexpression.
Activated immune cells play an important role in cardiovascular in-
flammation by removing cell debris and pathogens, but chronic inflam-
mation such as in EAM leads to tissue injury.1 In fact, chemotaxis and
activation of splenocytes induced by TLR4-mediated up-regulation of
CCL2 and TNFa resulted in increased apoptotic cell death in vitro that
was inhibited by APN in our study. Furthermore, APN gene transfer in
EAM mice was associated with attenuation of myocardial apoptosis.
Tissue injury leads to release of extracellular matrix components such
as hyaluronan and fibronectin extra domain A (FDA), plasma proteins
(fibrinogen), and cytoplasmatic proteins (HSP60) that are able to acti-
vate TLR4 signalling and to induce apoptotic cell death.2,25 The import-
ance of TLR4 activation on cardiac and immune cells has been shown in
several injury models. In ischaemia–reperfusion injury, myocardial and
not immune cell TLR4 is the primary mediator for cardiac depression
as has been shown for sepsis-related cardiac dysfunction.26 In line with
our observations, Ao et al.27 demonstrated that myocardial tissue
TLR4 rather than neutrophil TLR4 is the determinant of neutrophil infil-
tration following I/R, implicating TLR4 in the homing of leucocytes fol-
lowing tissue injury and inflammation.
Other mechanisms having been shown to be involved in cardiopro-
tection in EAM are suppression of TLR4-dependent DC activation and
priming as well as inhibition of differentiation of T cells.6 Timely activa-
tionofTLR4 (innate immunity) togetherwithCD40(adaptive immunity)
on DCs is essential for the induction of EAM.6 Therefore, APN-induced
suppression of TLR4 signalling might interfere with differentiation, acti-
vation, and antigen presentation by DCs. In line with this hypothesis,
mice deficient in the downstream adaptor molecule MyD88 are pro-
tected from EAM since MyD88 signalling in DCs is essential to prime
Figure 5 APN attenuates TLR4-mediated migration of splenocytes and apoptosis of cardiomyocytes after co-cultivation with splenocytes. (A) Cardi-
omyocytes and fibroblasts were incubated with APN (10 mg/mL) or vehicle (Albumin 10 mg/mL) for 18 h before stimulation with or without LPS
(1 mg/mL) for 24 h. Migration of co-cultivated CFDA-labelled splenocytes towards cardiac cells was quantified by FACS (n ¼ 5). (B) Cardiomyocytes
were incubated with APN (10 mg/mL) or vehicle (Albumin 10 mg/mL) for 18 h before co-cultivation with splenocytes in the presence or absence of
LPS (1 mg/mL) for 24 h. Apoptosis of cardiomyocytes was quantified by TUNEL staining after removal of splenocytes. Upper panel: representative
images of TUNEL stained nuclei (red). Lower panel: related images of DAPI counterstained nuclei (blue). (C ) Box plot indicating the number of
TUNEL positive cells relative to the total number of cells (n ¼ 5).
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heart specific CD4+ T cells28 in a TNFa-dependent manner. TNFa has
an important role in the induction of EAM and was significantly down-
regulated following APN gene transfer in our study. In vitro blocking of
TNFa by a specific antibody inhibits antigen-specific DC priming and
proliferation of CD4+ T cells and recombinant TNFa restores prolif-
erative responses of CD4+ T cells in MyD88 deficient DCs, indicating
that MyD88-regulated TNFa is important for CD4+ T cell-dependent
EAM in our model.28 Therefore, down-regulation of TNFa by APN
might inhibit EAM by attenuating priming of CD4+ T cells. In this
regard, APN inhibited the up-regulation of TNFa in DCs, the activation
of DCs and the DC-mediated priming of antigen-specific T cells follow-
ing TLR4 ligation in our study. Moreover, TLR4-deficient mice develop
markedly reduced myocarditis after infection with enterovirus.29
Further, we have recently shown APN to inhibit the expansion of
antigen-specific T cells by attenuation of proliferation and induction of
apoptosis.10 Although this process is not TLR4-dependent, APN-
mediated diminished proliferation of myosin-specific T cells might at-
tenuate tissue injury in our CD4+ T cell-dependent EAM model.
One limitation of the study is not being able to use APN deficient mice
in our in vivo model because of a different background (C57BL/6).
However, a life-time increase or absence of APN may induce changes
in multiple systems that may obscure direct modulatory effects of
APN on inflammation in vivo. Specific questions that arose from our
EAM in vivo studies could be confirmed in APN-deficient animals. There-
fore, confirming certain aspects, i.e. inhibition of TLR4 signalling by APN
in APN-KO mice together with results gathered in rat neonatal cardio-
myocytes and fibroblasts as well as human immune cells strengthen the
data obtained in BALB/c mice by providing evidence for a general applic-
ability of APN effects on TLR signalling.
In conclusion, our data implicate at least two different mechanisms for
protection resulting from APN overexpression in EAM. First, inhibition
of EAM induction by suppression of TLR4-dependent DC activation
resulting in attenuated initial priming of autoreactive CD4+ T cells.
Secondly, inhibition of EAM progression by down-regulation of
TLR4-dependent pro-inflammatory gene expression in cardiac and
immune cells resulting in attenuated activation and interaction of both
cell types limiting myocardial injury.
Beyond EAM, our findings have wider implications and may account for
a multitude of anti-inflammatory effects described for APN since en-
dogenous ligands of TLR4 are released in multiple types of cardiovascular
injury.ThedescribedAPN-mediated inhibitionofTLR4signallingmightbe
a general anti-inflammatory mechanism confining inflammation in cardio-
vascular diseases among others in atherosclerosis,30 cardiac hypertrophy/
left-ventricular remodelling,3 sepsis, and inflammatory cardiomyopathy.13
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